HAYA Therapeutics
Programming lasting health
- Headquarters
- Lausanne
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- hayatx.com
- Total Funding
- $62.0M
- Last Round
- $62.0M Series AMay 2025
About
HAYA Therapeutics is a precision medicine company developing RNA-guided programmable therapeutics that target the regulatory genome — the 98% of the genome that doesn't code for proteins — to reverse disease-driving cell states. The company's platform integrates multimodal functional genomics with proprietary computational tools to discover and drug long non-coding RNAs (lncRNAs) that causally drive fibrotic and other serious diseases.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account